GlassScriptPhysician profile
James W Hansen
NPI 1275769846
$5,912.40
in general payments reported to CMS, 2019-2025
21 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.28 · 2020: $280 · 2021: $667 · 2022: $799 · 2023: $581 · 2024: $1,234 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105 · Travel and Lodging: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,105.39 |
| Travel and Lodging | $999.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,704.22 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abbott Laboratories | $575.98 | 2021-2024 | Mitraclip |
| Medtronic, INC. | $538.73 | 2021-2024 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $330.86 | 2021-2025 | |
| Abiomed | $311.37 | 2022-2024 | Impella |
| Medtronic Vascular, INC. | $279.75 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $197.86 | 2021-2025 | Eliquis |
| Novo Nordisk INC | $169.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $157.03 | 2021-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $140.42 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Janssen Pharmaceuticals, INC | $76.49 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.63 | 2024-2025 | Jardiance |
| Shockwave Medical, INC | $64.27 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $63.45 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $50.58 | 2021-2023 | Verquvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.17 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.14 | 2021-2024 | Lifevest |
| Cardiovascular Systems INC. | $31.38 | 2021-2022 | |
| Becton, Dickinson and Company | $24.05 | 2024 | Lutonix Drug Coated Balloon |
| Sanofi-Aventis U.S. LLC | $17.12 | 2023 | |
| Amarin Pharma, INC. | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.